These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17671332)

  • 61. Perfluorooctylbromide nanoparticles for ultrasound imaging and drug delivery.
    Li X; Sui Z; Li X; Xu W; Guo Q; Sun J; Jing F
    Int J Nanomedicine; 2018; 13():3053-3067. PubMed ID: 29872293
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Wang J; Scollard DA; Mondal H; Holloway C; Kahn HJ; Reilly RM
    Nucl Med Biol; 2005 Jan; 32(1):51-8. PubMed ID: 15691661
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Optimized Fabrication of Nanobubbles as Ultrasound Contrast Agents for Tumor Imaging.
    Cai WB; Yang HL; Zhang J; Yin JK; Yang YL; Yuan LJ; Zhang L; Duan YY
    Sci Rep; 2015 Sep; 5():13725. PubMed ID: 26333917
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer.
    Lv W; Shen Y; Yang H; Yang R; Cai W; Zhang J; Yuan L; Duan Y; Zhang L
    J Immunol Res; 2018; 2018():6202876. PubMed ID: 29854844
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Coating microbubbles with nanoparticles for medical imaging and drug delivery.
    Tay LM; Xu C
    Nanomedicine (Lond); 2017 Jan; 12(2):91-94. PubMed ID: 27876447
    [No Abstract]   [Full Text] [Related]  

  • 66. Nano-pharmaceutical formulations for targeted drug delivery against HER2 in breast cancer.
    Sadat SM; Saeidnia S; Nazarali AJ; Haddadi A
    Curr Cancer Drug Targets; 2015; 15(1):71-86. PubMed ID: 25564255
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Nanobubble-Affibody: Novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumor.
    Yang H; Cai W; Xu L; Lv X; Qiao Y; Li P; Wu H; Yang Y; Zhang L; Duan Y
    Biomaterials; 2015 Jan; 37():279-88. PubMed ID: 25453958
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Polymeric contrast agent with targeting potential.
    Lathia JD; Leodore L; Wheatley MA
    Ultrasonics; 2004 Apr; 42(1-9):763-8. PubMed ID: 15047380
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle.
    Liu X; Nakamura K; Wang Y; Cheng D; Liang M; Xiao N; Chen L; Rusckowski M; Hnatowich DJ
    J Biomed Nanotechnol; 2010 Apr; 6(2):153-7. PubMed ID: 20738069
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Optimization of Phase-Change Contrast Agents for Targeting MDA-MB-231 Breast Cancer Cells.
    Hadinger KP; Marshalek JP; Sheeran PS; Dayton PA; Matsunaga TO
    Ultrasound Med Biol; 2018 Dec; 44(12):2728-2738. PubMed ID: 30228045
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Staphylococcus aureus-mimetic control of antibody orientation on nanoparticles.
    Shim G; Kim D; Lee S; Chang RS; Byun J; Oh YK
    Nanomedicine; 2019 Feb; 16():267-277. PubMed ID: 30368001
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effect of particle density on ultrasound-mediated transport of nanoparticles.
    Lea-Banks H; Teo B; Stride E; Coussios CC
    Phys Med Biol; 2016 Nov; 61(22):7906-7918. PubMed ID: 27779121
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Possible target specific molecular imaging with ultrasound contrast agents].
    Mäurer M; Linker R; Reinhardt M; Hauff P
    Radiologe; 2005 Jun; 45(6):560-8. PubMed ID: 15912322
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Polymer-Based Materials in Cancer Treatment: From Therapeutic Carrier and Ultrasound Contrast Agent to Theranostic Applications.
    Methachan B; Thanapprapasr K
    Ultrasound Med Biol; 2017 Jan; 43(1):69-82. PubMed ID: 27751594
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intracellular delivery and ultrasonic activation of folate receptor-targeted phase-change contrast agents in breast cancer cells in vitro.
    Marshalek JP; Sheeran PS; Ingram P; Dayton PA; Witte RS; Matsunaga TO
    J Control Release; 2016 Dec; 243():69-77. PubMed ID: 27686582
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparing the intracellular fate of components within a noncovalent streptavidin nanoparticle with covalent conjugation.
    Liu Y; Cheng D; Liu X; Liu G; Dou S; Xiao N; Chen L; Rusckowski M; Hnatowich DJ
    Nucl Med Biol; 2012 Jan; 39(1):101-7. PubMed ID: 21958854
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Nanosized Ultrasound Enhanced-Contrast Agent for in Vivo Tumor Imaging via Intravenous Injection.
    Kim M; Lee JH; Kim SE; Kang SS; Tae G
    ACS Appl Mater Interfaces; 2016 Apr; 8(13):8409-18. PubMed ID: 27010717
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies.
    Colombo M; Fiandra L; Alessio G; Mazzucchelli S; Nebuloni M; De Palma C; Kantner K; Pelaz B; Rotem R; Corsi F; Parak WJ; Prosperi D
    Nat Commun; 2016 Dec; 7():13818. PubMed ID: 27991503
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Single-domain antibody C7b for address delivery of nanoparticles to HER2-positive cancers.
    Vorotnikov YA; Novikova ED; Solovieva AO; Shanshin DV; Tsygankova AR; Shcherbakov DN; Efremova OA; Shestopalov MA
    Nanoscale; 2020 Nov; 12(42):21885-21894. PubMed ID: 33107540
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Targeted nanodiamonds as phenotype-specific photoacoustic contrast agents for breast cancer.
    Zhang T; Cui H; Fang CY; Cheng K; Yang X; Chang HC; Forrest ML
    Nanomedicine (Lond); 2015 Mar; 10(4):573-87. PubMed ID: 25723091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.